PDGFB and esophageal squamous cell carcinoma: Crenolanib is known to inhibit platelet-derived growth factor α/β (PDGFR α/β) signaling by targeting PDGF itself, thereby having the potential to inhibit DNM3OS. Moreover, a higher expression of PDGF β-polypeptide (PDGFβ), and platelet-derived growth factor receptor β-polypeptide (PDGFβR) observed in ESCC cell lines (KYSE-30 and KYSE-140) cultured in CAF-containing condition-media as compared to the controls [12].